肿瘤免疫治疗中T细胞抗原表位的识别

xyu201

Identification of T-cell epitopes for cancer immunotherapy
The effectiveness of T-cell-mediated immunotherapy of cancer depends on both an optimal immunostimulatory context of the therapy and the proper selection with respect to quality and quantity of the targeted tumor-associated antigens (TAA), and, more precisely, the T-cell epitopes contained in these tumor proteins.
T细胞介导肿瘤免疫治疗的疗效不仅取决于最适免疫刺激，而且取决于靶向性肿瘤相关抗原更准确的说是包含这些肿瘤蛋白的T细胞抗原表位的质和量的合适选择。
Our progressing insight in human leukocyte antigen (HLA) class I and class II antigen processing and presentation mechanisms has improved the prediction by reverse immunology of novel cytotoxic T lymphocyte and T-helper cell epitopes within known antigens.
我们对人类白细胞抗原加工提呈机制的进一步理解促进了利用反向免疫学从已知抗原中对异常细胞毒性T淋巴细胞和辅助性T淋巴细胞抗原表位的预测。
Computer algorithms that in silico predict HLA class I and class II binding, proteasome cleavage patterns and transporter associated with antigen processing translocation are now available to expedite epitope identification.
使用计算机算法预测HLAⅠ型Ⅱ型抗原结合、蛋白酶体裂型及抗原加工相关转运子易位加速了对抗原表位的识别。
The advent of genomics allows a high-throughput screening for tumor-specific transcripts and mutations, with that identifying novel shared and unique TAA.
基因组学的到来使高通量筛选肿瘤特异性转录和突变成为可能，随即能够识别异常的共用及单一肿瘤相关抗原。
The increasing power of mass spectrometry and proteomics will lead to the direct identification from the tumor cell surface of numerous novel tumor-specific HLA class I and class II presented ligands.
质谱分析法和蛋白组学的日渐普及将是我们能够从肿瘤细胞表面直接识别为数众多的肿瘤特异性HLAⅠ型和Ⅱ型抗原提呈位点。
Together, the expanded repertoire of tumor-specific T-cell epitopes will enable more precise immunomonitoring and the development of effective epitope-defined adoptive T-cell transfer and multi-epitope-based vaccination strategies targeting epitopes derived from a wider diversity of TAA presented in a broader array of HLA molecules.
肿瘤相关T细胞抗原表位所有组分的识别将提供更为精确的免疫监视，并促进靶向来源于HLA分子芯片分析的大量TAA的特定抗原表位的T细胞过继转移及多抗原表位联合疫苗策略的进展。